Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Hims & Hers Health Inc (NY: HIMS )

23.42 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Hims & Hers Health Inc

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
17 18 Next >
Earnings Scheduled For February 26, 2024
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.23 per share on revenue of $477.73 million. 
Via Benzinga
Earnings Preview: Hims & Hers Health
Via Benzinga
Where Will Hims & Hers Stock Be in 5 Years?
This unique telemedicine company looks poised for a bright future. 
Via The Motley Fool
1 Healthcare Stock to Buy Hand Over Fist Going Into 2024
Hims & Hers Health is growing at an unprecedented rate. 
Via The Motley Fool
Hims & Hers Names Dan Kenger as the Company’s First Chief Design Officer
From Hims & Hers Health, Inc.
Via Business Wire
Hims & Hers to Announce Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024
From Hims & Hers Health, Inc.
Via Business Wire
3 Small-Cap Healthcare Stocks to Buy and Hold Forever: January 2024
Small-cap healthcare stocks combine relative cheapness with advanced innovations including AI, automation, and more. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
7 Growth Stocks to Buy and Hold Forever: January 2024
Growth stocks haven't kept up with wider market growth, creating a unique opportunity to capture long-term upside with these companies. 
Via InvestorPlace
It Is Time To Buy Hims & Hers Stock
Hims & Hers is a pharmaceutical marketing, product, and distribution firm with a telehealth component. 
Via Talk Markets
Is Hims & Hers Stock a Buy Now?
Investors may be overlooking an incredible growth opportunity with Hims & Hers stock. 
Via The Motley Fool
Got $1,000? 3 Growth Stocks to Buy That Could Double Your Money
Healthcare is nearly a fifth of America's economy. Ride these high-flying healthcare stocks to monster gains. 
Via The Motley Fool
Topics Economy
Exposures Economy
3 Stocks to Profit from the Telehealth Transformation
Telehealth stocks capture healthcare and medicine's future but don't bet the bank on a company that can't cut it. 
Via InvestorPlace
Hims & Hers Teams with Hartford HealthCare to Connect People to In-person Care
From Hims & Hers Health, Inc.
Via Business Wire
Underestimating This Stock Could Be Wall Street's Biggest Mistake in 2024
Hard numbers and the CEO's own words point to shares exploding next year. 
Via The Motley Fool
Weight Watchers gains from Oprah’s GLP-1 weight-loss
Oprah Winfrey revealed she has lost over 60 pounds and is on the path to reaching her weight goal of 167 lbs. She credits this to taking GLP-1 medication 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
2023 Year In Review
The S&P 500 had a strong year in 2023, returning about 24% to investors from the beginning of the year to the end. Some of that was a bounce back from a poor 2022 when it was down over 11%. 
Via Talk Markets
Topics Stocks
Exposures US Equities
The 3 Hottest Telehealth Stocks to Watch in 2024
Uncover the hottest telehealth stocks for 2024, on the back of a market projected to reach a whopping $504.2 billion by 2030. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
LifeMD expands telehealth GLP-1weight-loss service with Medifast
LifeMD Inc. (NASDAQ: LFMD) is a direct-to-consumer (DTC) comprehensive virtual healthcare platform. The company offers per-visit and membership plan pricing 
Via MarketBeat
My 2024 Financial Resolution: Buying More of These 3 Stocks
These stocks are still screaming buys for my long-term portfolio. 
Via The Motley Fool
Ozempic vs. Mounjaro:: Battle of the bulge
The year 2023 was a breakout year for glucagon-like peptide (GLP-1) weight-loss drugs, led by the popularity of Ozempic. Celebrity usage 
Via MarketBeat
Exposures Product Safety
Hims & Hers Launches Holistic Weight Loss Program to Break the Endless Cycle of Weight Gain and Loss
From Hims & Hers Health, Inc.
Via Business Wire
This Growth Stock Could 10x in 10 Years
This emerging consumer healthcare company could compound at more than 25% annually. 
Via The Motley Fool
Hims & Hers earnings highlight expanded personalized treatments
E-health and wellness platform operator Hims & Hers Inc. reported a stellar quarter of growth that highlighted its expanded line of personalized products 
Via MarketBeat
5 Telehealth Stocks That Have Nothing But Upside
Dive into the dynamic world of top telehealth stocks. Discover our expert analysis on the gems shaping the future of digital healthcare. 
Via InvestorPlace
My Take: 4 Strong Growth Stocks to Buy This Week
Be thankful for Wall Street's discounts on these potential market-beating stock ideas. 
Via The Motley Fool
2 No-Brainer Stocks to Buy Right Now for Less Than $50
These rapidly expanding companies could make you richer, even with a minimal investment. 
Via The Motley Fool
2024’s Hidden Gems: 7 Small-Caps Set for Explosive Growth
Small-cap stocks outperform larger companies on an indexed basis, but finding the best among them individually isn't always easy. 
Via InvestorPlace
Top 5 Health Care Stocks That May Collapse In November
As of Nov. 17, 2023, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. 
Via Benzinga
Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers PaxMedica, Inc. (NASDAQ: PXMD) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2 study results in the Annals of General Psychiatry. 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
17 18 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.